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Temozolomide is a poorly soluble anti-cancer drug used in the treatment of some brain cancers. 
Following literature reports about the enhancement of solubility and stability for these kinds of drugs 
upon complexation with cyclodextrins, we aimed to form an inclusion complex between temozolomide 
and the different types of cyclodextrins (CDs) to enhance its solubility. In this study, three different 
cyclodextrins (β-CD, hydroxyl-β-CD and γ-CD) were used, and changes in solubility was measured by 
UV-Vis Spectroscopy and HPLC. Morphological changes upon complexation were shown by the Scanning 
Electron Microscope (SEM), and weight loss profiles with respect to temperatures which were unique to 
the compounds were shown by Thermogravimetric Analysis. Changes in heat release profiles were shown 
by Differential Scanning Calorimeter (DSC). Drug solubility was measured to be increased to around 25% 
for 1:1 molar ratio for all used CD complexations. Changes of morphology, heat release and weight loss 
profiles are consistent with the formation of an inclusion complex between CDs and temozolomide. In 
this study, success was shown in the enhancement of temozolomide solubility upon complexation with 
different types of CDs. It has been demonstrated that cyclodextrins can be used as complexing agents 
for poorly soluble anti-cancer drugs, increasing their solubility and hence drug availability.
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INTRODUCTION
Temozolomide (TMZ) is a second generation 
imidazotetrazinone derivative with methylating 
properties. It is used as an oral cytotoxic agent for 
adjuvant chemotherapy in malignant primary brain 
tumors such as glioblastoma (Stupp et al., 2005) 
and malignant glioma (glioblastoma multiforme and 
anaplastic astrocytoma) (Brada et al., 1999; Marchesi 
et al., 2007). The drug contains an imidazole group 
connected to a tetrazole ring (Figure 1) (Khan et al., 
2016). Due to its relatively high cytotoxicity for cancer 
cells, TMZ is commonly preferred by clinicians (Payne, 
Pratap, Middleton, 2005). TMZ is more of a prodrug and 
its chemical decomposition to 3-methyl-(triazen-1-yl) 
imidazole-4-carboxamide (MTIC) alkylates nucleophiles 
(i.e. DNA) and causes cell death (Kim et al., 2001). This 
process is highly pH dependent since TMZ exerts in vivo 
activity by spontaneous hydroxylation at a physiologic 
pH (Andrasi et al., 2010).
TMZ brings additional benefits, so that it helps 
the crossing of DTIC (5-(3,3-dimethyl-1-triazenyl) 
imidazole-4-carboxamide) analogues through the blood 
brain barrier, which is another member of the alkylating 
agent class with a similar mechanism of action in metastatic 
melanoma. It is known that metastatic melanoma 
frequently metastasizes to the brain (Zuckerman et al., 
2011). It is important to deliver an appropriate level of the 
active chemotherapeutic agent to the tumor area to cross 
the blood brain barrier. Aqueous solubility is known as 
one of the major concerns of conventional chemotherapy 
FIGURE 1 - Structure of TMZ.
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due to the mostly non-polar nature of chemotherapeutic 
agents (Chidambaram, Manavalan, Kathiresan, 2011). As 
a result, various delivery vehicles can be used to increase 
the solubility of conventional chemotherapy selectivity. 
Apart from solubility, the chemical stability of TMZ is 
also worth consideration. Once TMZ is delivered in the 
body, it quickly decomposes to its active agent, MTIC, 
at a neutral pH. Therefore, any delivery vehicle of the 
drug should be prepared in the acidic solution and then 
lyophilized for stability.
Cyclodextrins (CDs) are molecular chelating 
agents belonging to a class of cyclic oligosaccharides 
which consist of (α-1,4)-linked α-D-glucopyranose 
units. These compounds contain a lipophilic inner cavity 
and a hydrophilic outer surface. CDs have significant 
capacities to form inclusion complexes according 
to their core-shell structure. As a result of molecular 
complexation, these molecules are appropriate hosts 
to be used for drug-delivery, many industrial products, 
technologies and analytical methods (Loftsson et al., 
2002; Del Valle, 2004; Loftsson et al., 2005). Natural CD 
and its synthetic derivatives can be employed to enhance 
certain physicochemical properties of the drug such as 
dissolution, solubility, stability or release rates (Uekama, 
Otagiri, 1987). There are different derivatives of CDs, 
but β-CD is the most commonly used form, because it is 
easily produced and cheaper with respect to the others. 
Depending on the number of sugar units in cyclodextrins, 
the cavity size can be altered to accommodate different 
drugs. α, β, γ cyclodextrins refer to the sugar unit numbers 
of 6, 7 and 8, respectively. Apart from tailoring the cavity 
size, the solubility of cyclodextrins in aqueous medium 
can also be modified by hydroxypropyl, methyl or sulfo-
butyl ether to derive the structure (Loftsson et al., 2005; 
Uekama, Otagiri, 1987). 
Solubility and stability of various host agents of 
pharmaceutical agents, such as protein and peptide, 
steroids or low molecular weight agents, have been studied 
and improved by using natural or synthetic kinds of CD 
compounds. The inclusion complexation of this host-guest 
systems exhibits considerable intramolecular interactions, 
such as hydrogen bonding, hydrophobic interactions or 
electrostatic attractions (Uekama, Otagiri, 1987; Aiassa et 
al., 2015). The formation of an inclusion complex between 
TMZ and β-CD is schematically shown in Figure 2. 
Generally, drugs should be sufficiently hydrophobic 
in order to penetrate biological membranes via passive 
diffusion, but at the same time possess some hydrophilicity 
in aqueous medium. For many pharmaceutical applications, 
it was shown that inclusion complex helped to improve 
solubility (Aiassa et al., 2015; Atipairin, Sawatdee, 2016; 
Freitas et al., 2012; Ol’khovich et al., 2014; Priya et al., 
2013; Shende et al., 2015; Zhang et al., 2013a; Zhang et 
al., 2013b; Franco et al., 2009; Ruan et al., 2005; Tang 
et al., 2015; De Araujo et al., 2008), stability (Freitas 
et al., 2012; Shende et al., 2015; Kicuntod et al., 2016), 
bioavailability (Atipairin, Sawatdee, 2016; Zhang et 
al., 2013a), and therapeutic effect (Zhang et al., 2013b), 
between various drugs and cyclodextrins. Inclusion 
complexes of epothilone (Xiao et al., 2014), oxaliplatin 
(Zhang et al., 2016), paclitaxel (Hamada et al., 2006), etc. 
were found to be effective for anti-tumor therapy. 
The size of the hydrophobic cavity depends on 
the number of sugar units; hence solubility depends on 
derivation of the cyclodextrin where both may play a role 
in the optimization of complex formation. In the present 
study, three different cyclodextrins (β-cyclodextrin 
(β-CD), 2-hydroxy propyl-β-cyclodextrin (H-β-CD), 2- 
hydroxypropyl-γ-cyclodextrin (H-γ-CD) were employed 
to optimize the complex formation. The solubility of TMZ 
in water is quite low. Enhancing its solubility would be 
a great achievement. In the present study, we aimed to 
enhance the solubility of TMZ by using different kinds 
of cyclodextrins. We employed several techniques to 
show that an inclusion complex between the drug and 
CDs were formed, which was responsible for solubility 
enhancement.
MATERIAL AND METHODS
Material 
TMZ (99.38%) was donated by Kocak Farma, 
Istanbul, Turkey. Hydrochloric acid (37%, Sigma 
Aldrich), acetic acid (≥99.8%, Sigma Aldrich), and 
methanol (99.7%, Sigma Aldrich) were also received and 
used without any chemical procedures. β-cyclodextrin 
(β-CD), hydroxypropyl-β-cyclodextrin (H-β-CD), and 
hydroxypropyl-γ cyclodextrin (H-γ CD) were purchased 
FIGURE 2 - Inclusion complex between TMZ and β-cyclodextrin.
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from Sigma Aldrich. The water used was distilled by 
reverse osmosis using GFL 2004.
Determination of the solubility of TMZ 
Saturation of TMZ concentration was determined 
by adding an arbitrary amount of excess TMZ in 5 mL 
0.1 M HCl. After vortexing, followed by sonication for 2 
minutes, the excess TMZ was removed by centrifugation. 
The amount of TMZ in the supernatant was determined by 
UV-Vis Spectroscopy (BioSpec-1601 Shimadzu, Japan), 
measuring absorbance at 330 nm. Once this concentration 
was determined, TMZ solutions of lower concentrations 
were prepared by dissolving different amounts of the 
drug again in 5 mL 0.1 M HCl and measuring their 
absorbance values. HCl was used as a solvent to prevent 
decomposition of the drug into its active agent at neutral 
pH (Babu, Sanphui, Nangia, 2012).
Preparation of TMZ-cyclodextrin inclusion 
complex solutions
The complexes of  TMZ were formed with 
three different cyclodextrins β-cyclodextrin (β-
CD), hydroxypropyl-β-cyclodextrin (H-β-CD), and 
hydroxypropyl-γ-cyclodextrin (H-γ-CD) that contain six to 
eight membered rings. TMZ:CD solutions were prepared 
at different molar ratios as 1:1, 1:2 and 1:5. 
Briefly, the required amount of cyclodextrin was 
first weighed and a 0.1 M HCl solution was added to 
obtain a total amount of 0.5 g solution. An excess amount 
of TMZ (7.25 mg, i.e. approximately two times higher 
than its solubility) was weighed separately and the 
cyclodextrin solution (0.5 g) was added to the weighed 
TMZ and the resulting solution was vortexed. After 
vortexing, 0.1 M HCl was added to the solution in order 
to obtain a 1.0 g solution. This solution was then shaken 
at 250 rpm at 37 for one hour using an orbital shaker 
(LABWIT, ZWYR-240, Ashwood, Australian), followed 
by centrifugation (Hettich, EBA 21,Beverly, USA) at 
6000 rpm for 5 minutes. The supernatant was freeze-dried 
(SCANVAC, cool-safe, Lynge, Denmark) to obtain the 
TMZ-CD complex. The same procedure was applied for 
all cyclodextrins (Del Valle, 2004; Loftsson et al., 2005). 
The preparation process of TMZ-CD inclusion complex 
is schematically shown in Figure 3.
Preparation of TMZ-cyclodextrin physical mixtures
Excess amount of TMZ (7.25 mg) was mixed with 
26.5 mg β-CD (1:5 mol ratio) in the solid phase using a 
spatula and kept at 4 oC until measurements. SEM, DSC 
and TGA measurements were all carried out in the solid 
phase.
Complex formation of TMZ-CD
Scanning electron microscopy (SEM, JEOL Ltd., 
JSM-5910LV, Akishima, Japan) was used to observe 
the morphologies of TMZ, CD, TMZ-CD complex 
and the TMZ-CD physical mixture. The difference 
FIGURE 3 - Preparation process of TMZ-CD inclusion complex.
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in morphology of the TMZ-CD complex and TMZ-
CD physical mixture is interpreted as a support 
for the formation of the complex. DSC (Setaram 
instrumentation, DSC 131, Caluire, France) was used 
to compare the endothermic and exothermic peaks of 
TMZ, CD, TMZ-CD complex and TMZ-CD physical 
mixture. In the physical mixture, the TMZ and CD peaks 
are expected to remain in the original positions of TMZ 
and CD, whereas upon complexation new peaks are 
expected to appear, indicating the formation of a new 
entity. A thermogravimetric analysis (Perkin Elmer, Pyris 
1 TGA, Beacousfield, England) was performed for the 
same systems. Again, upon complexation the baseline 
temperatures are expected to change, whereas for the 
physical mixture, the baseline temperatures should be 
identical with the CD and TMZ.
Enhancement of solubility of TMZ
In order to investigate if TMZ-CD complexation 
enhances solubility of TMZ, after mixing, the solution was 
shaken at 300 rpm for 24 hours at 37 oC. The undissolved 
TMZ was removed by centrifuging at 6000 rpm for 5 
minutes. The supernatant was then diluted 200 times with 
0.1 M HCl to measure the amount of solubilized TMZ 
using UV-Vis Spectrophotometer in the 200-450 nm 
range following TMZ max absorbance value at 330 nm 
and HPLC. The HPLC system consists of 1525 Binary 
Pump, 2487 UV-Vis Detector, 717 Autosampler and a 
thermal column manager unit. A computer was also used to 
process raw data. In the HPLC reverse phase C18 column 
(X-Bridge 150 mm x 0.6 cm, 0.5 μm, Waters was used. 
Water containing 0.5% acetic acid / methanol (80:20 v/v) 
was prepared for the mobile phase. A standard calibration 
curve was obtained with five different TMZ concentrations 
(R2= 0.998) and three samples were used, and each sample 
from three injections was measured.
RESULTS 
Solubility curve 
As the concentration of TMZ increases, its 
absorbance at 200 nm increases linearly up to a critical 
concentration above which the absorbance value remains 
constant, regardless of increase in the amount of TMZ in 
the solution. This critical concentration gives the solubility 
value of TMZ in water at room temperature. By measuring 
absorbance values at 330 nm, the Temozolomide solubility 
was determined as 3.46 mg/mL (Figure 4). 
Complex formation
In order to show that a complex was formed between 
the TMZ and CDs, different techniques were employed. In 
all measurements, TMZ, CD, TMZ-CD physical mixture 
FIGURE 4 - Absorbance of TMZ at 330 nm for different concentrations where the minimum concentration for maximum absorbance 
denotes the solubility of TMZ. 
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(1:1) and TMZ-CD complex (1:1) were compared. SEM 
was used to show clear morphology changes which 
occurred upon complex formation. In Figure 5a and b, 
the TMZ and β-CD morphologies are observed. In the 
physical mixture (Figure 5c), the individual TMZ and 
β-CD morphologies could be identified. Upon formation 
of a complex, a new morphology was observed where 
neither TMZ nor β-CD could be distinguished. 
Another technique employed was TGA. TGA 
showed the weight loss of materials upon heating. 
Weight loss occurs due to decomposition of material, 
and the baseline temperature of this decomposition was 
particular for the compound. As a result, it can be used as 
a verification tool for that compound. 
In Figure 6, the dark blue line shows the weight loss 
profile of TMZ, with a baseline temperature of 229 oC. 
The green line is the weight loss profile of β-CD, with a 
baseline temperature of 353 oC.
The initial weight loss observed until about 100oC is 
due to the water loss in the structure (Zhang et al., 2013b; 
Trotta, Zanetti, Camino, 2000). In the physical mixture 
(yellow line), two baseline temperatures were observed, 
one can be associated with TMZ (227 oC) and the other 
with β-CD (351 oC). The baseline values were very similar 
to those of pure TMZ and β-CD, which was expected 
from the physical mixture. In the complex, two baseline 
temperatures from TMZ and β-CD were observed, with 
temperature shifts of 7 and 15 oC, respectively. 
DSC measured the heat flow with respect to 
temperature. In Figure 7, the temperature scan in the range 
of 25 oC and 250 oC exhibited an exothermic peak around 
209 oC for TMZ, which showed that heat was released 
upon decomposition of TMZ. In this temperature range, 
an endothermic peak around 140oC for β-CD was observed 
which was related to the dehydration of β-CD. It should be 
noted that these temperatures are comparable with those 
observed in TGA as decomposition and water loss. The 
mass loss value calculated from the thermogravimetric 
curve in the range of this effect was around 60%.
In the physical mixture, the endothermic peak of 
dehydration from β-CD and the exothermic peak from 
the decomposition of TMZ were both present at the exact 
temperature locations of TMZ and β-CD. In the inclusion 
complex, neither of these peaks was visible. All inclusion 
complex verification experiments (SEM, TGA, DSC) 
were also performed with 2-hydroxy propyl-β-CD and 
2-hydroxy propyl-γ-CD, presenting similar conclusions. 
Data is not shown to avoid repetition.
Enhancement of solubility of TMZ
The amount of solubilized TMZ in the TMZ-CD 
complexes was measured after 24 hours of using a 
spectrophotometer, taking the data at 330 nm, where the 
signature peak of TMZ existed. CD did not have a peak 
in the UV region, so all the signals came from TMZ. The 
FIGURE 5 - SEM images of (a) TMZ, (b) β-CD, (c) TMZ and β-CD physical mixture where free TMZ and β-CD are clearly marked 
with arrows (d) TMZ and β-CD inclusion complex where a new structure without free TMZ is revealed.
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amount of solubilized TMZ in all CD mixtures is shown 
in Table I.
In Figure 8, it was clearly showed that the amount 
of solubilized TMZ was higher in the presence of CDs 
regardless of the type of CD used. 
In order to more accurately measure the concentration 
of solubilized TMZ in the presence of different CDs as 
well as in their different mixing ratios after one hour and 
24 hours, the HPLC method was used. The results are 
demonstrated in Table II which shows that the amount 
of TMZ solubilized does not change from one hour to 24 
hours.
The solubilized amount of TMZ in the presence of 
different CDs after one hour is plotted in Figure 9.
FIGURE 6 - TGA curves of TMZ-β-CD inclusion complex and physical mixing.
FIGURE 7 - DSC curves of TMZ-β-CD inclusion complex and physical mixing.
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Solubility enhancements of about 25% are obtained 
by using different types of CDs. These results showed that 
TMZ solubility increased as the CD amount in the mixing 
ratio increased; however, this increase was not found to be 
proportional to the added CD. It is suggested that the 1:1 
mixing ratio was sufficient to be used in this system and an 
enhancement in solubility of about 25% could be achieved. 
DISCUSSION
Solubility and hence bioavailability of temozolomide 
have difficulties of enhancement, as a result no studies have 
been performed to in the literature. In the present study, 
it is suggested that cyclodextrins may be good agents to 
help resolve chemical issues through complexation of the 
drug. Literature studies have indicated that hydrophobic 
drugs could form inclusion complexes with cyclodextrins 
(Freitas et al., 2012; Ol’khovich et al., 2014). In line with 
the literature, three cyclodextrins used in the present study 
with different hydrophilicities and different hydrophobic 
cavity sizes optimized complexation with temozolomide 
(Xiao et al., 2014; Zhang et al., 2016; Hamada et al., 
2006). In order to ensure that there is indeed complexation 
and not just a physical mixture between temozolomide 
and CDs, the morphological differences between physical 
mixture and the product obtained using SEM, along 
with differences in weight loss and heat loss profiles, 
using TGA and DSC, respectively were investigated. 
In the SEM images in Figure 5, both TMZ and CD are 
clearly distinguished in the physical mixture (Figure 5c), 
whereas a new morphology is observed for the complex 
(Figure 5d). These results are similar to those obtained 
by Maestrelli et al. (2010) where upon the formation 
of an inclusion complex, neither the drug nor the CD is 
distinguished in the SEM images, but a new morphology 
is observed. 
The TGA data shown in Figure 6 clearly indicate the 
difference between the physical mixture and the complex. 
In the physical mixture, the baseline temperatures for 
weight loss are very similar to those of the constituents 
alone, whereas in the complex a new weight loss profile 
is clearly visible. In the physical mixture, baseline 
temperatures of TMZ and β-CD appear at the exact 
TABLE I - Amount of solubilized TMZ in mg/mL in 0.1 M HCl 
after the formation of inclusion complex after 24 hours
Formulations 1 mol TMZ: 1 mol CD (mg/mL) % Enhancement
Only TMZ 3.46±0.07
β-CD-TMZ 4.34±0.06 25
Hydroxy-β-CD-
TMZ
4.97±0.12 43
Hydroxy-γ-CD-
TMZ
4.32±0.06 25
FIGURE 8 - Amount of solubilized TMZ in mg/mL in 0.1 M HCl in the presence of different CDs in 1:1 ratio after the formation 
of inclusion complex after 24 hours (UV-Vis results).
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temperatures. On the other hand, in the complex, two 
baseline temperatures of TMZ and β-CD were observed, 
but with temperature shifts of 7 and 15 oC, respectively, 
which was quite significant, indicating the interaction 
of TMZ and β-CD at the complexation level. Baseline 
temperatures are often used in the verification of a 
compound (Widmann, 2000). Shifts in the baseline 
temperatures and new weight loss profiles upon complex 
formation have been obtained by other researchers 
(Banerjee, Chen, 2007) and therefore used as an additional 
support for the formation of an inclusion complex between 
TMZ and β-CD. DSC (Figure 7) results can also be 
interpreted in a similar fashion where the physical mixture 
exhibits similar heat profiles to its pure constituents, and 
the complex has a totally different heat profile in the same 
temperature region, indicating the formation of a new 
complex. Somewhat similar endothermic dehydration 
is still observed, expected from the water being lost 
from β-CD. However, the exothermic decomposition 
peak of TMZ completely disappears from its relevant 
position. In the literature, DSC profiles of cyclodextrin 
inclusion complexes with salbutamol (Marques, Hadgraft, 
Kellaway, 1990) and quercetin (Pralhad, Rajendrakumar, 
2004) have been investigated and were shown to possess 
their unique heat loss profile, significantly exempted from 
the exothermic decomposition peak of the drug, showing 
that the drug participates in the inclusion complex. All the 
methods employed for the confirmation of the formation 
of an inclusion complex show that a complex has indeed 
formed between TMZ and CDs, and its study properties 
are significantly different from that of the physical mixture. 
The solubility of temozolomide in water was determined 
using UV absorbance as shown in Figure 4 to be 3.46 
mg/mL. In literature, this value is stated as 5.09 mg/mL 
based on the ALOGPS calculations (http://www.vcclab.
org) However, it is expected that experimental values 
may not correspond exactly with the calculated values. 
The solubility values obtained from UV are consistent 
TABLE II - Amount of solubilized TMZ in mg/mL in 0.1 M HCl after the formation of inclusion complex after one hour and 24 hours
Formulations
1 mol TMZ: 1 mol CD 
(mg/mL)
1 mol TMZ: 2 mol CD 
(mg/mL)
1 mol TMZ:5 mol CD 
(mg/mL)
One hour 24 hours One hour 24 hours One hour 24 hours
Only TMZ 3.46 
β-CD-TMZ 4.23±0.16 4.23±0.40 4.43±0.14 4.31±0.49 4.59±0.07 4.51±0.07
Hydroxy-β-CD-TMZ 4.13±0.14 4.29±0.04 4.3±0.09 4.26±0.4 4.43±0.4 4.25±0.1
Hydroxy-γ-CD-TMZ 4.33±0.16 4.29±0.04 4.35±0.07 4.43±0.02 4.53±0.5 4.52±0.8
FIGURE 9 - Amount of solubilized TMZ in mg/mL in 0.1 M HCl after the formation of inclusion complex after one hour.
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with HPLC results reported in Table I, both indicating 
a solubility of around 3.5 mg/mL at 25 oC. Once this 
value was found, solubility enhancement experiments 
were conducted. These experiments have shown that in 
the presence of cyclodextrins, the solubility of the drug 
increases by about 25%, as clearly shown in Figure 9 
where the black line indicates the solubility of TMZ 
whereas the other data is of different complexes. One 
important finding is that the drug does not appear to have a 
significant preference towards either of the cyclodextrins, 
indicating that the cavity size is large enough for even 
the smallest sized ones (β-CD and H-γ-CD). Upon 
increasing the CD amount in the medium, the solubility 
of TMZ is further increased, but not in a linear fashion. 
This may suggest that there may be more than the simple 
one-to-one complexation mechanism taking place when 
the CD concentration is increased. It is likely that in the 
presence of high amounts of CD, one TMZ molecule 
may be complexing with more than one CD molecule, 
resulting in this nonlinear enhancement of solubility with 
increasing CD concentration. In literature, although there 
are some reports indicating a clear preference of the drug 
towards one of the CDs (Yoshida et al., 1989) or a linear 
increase in the solubility with increasing concentration 
(type A solubility), similar results to our findings have 
also been reported (type B solubility), where various types 
are described by Higuchi and Connors (1965). All these 
findings indicate the formation of inclusion complexes 
between temozolomide and different CDs, and these 
inclusion complexes enhancing the solubility of TMZ, 
which is very low in aqueous medium, by about 25%.
CONCLUSION
Temozolomide, an anti-cancer drug, which is quite 
unstable and insoluble in aqueous medium, is nearly 
impossible to be targeted in the body due to its severe 
side effects. In order to increase the solubility of this 
drug different cyclodextrins (β-CD, 2-hydroxy-propyl-
β-CD, 2-hydroxy-propyl-γ-CD) have been used, and 
the drug is shown to form an inclusion complex with 
these cyclodextrins by using SEM, TGA, DSC and 
HPLC. As a result of this complex formation, it has been 
shown that drug solubility is increased in the presence 
of cyclodextrins, regardless of the type cyclodextrin. 
Increasing the amount of cyclodextrin increases solubility 
in the complex, although not in a direct proportion. All 
experiments have been carried out in the acidic media 
to prevent hydrolysis of TMZ to its active agent, MTIC 
at neutral pH. Once solubility is enhanced, the drug-CD 
inclusion complex can be freeze-dried to be filled in a 
capsule, as it is formulated in the market. This study shows 
that cyclodextrins can be used as complexing agents for 
poorly soluble anti-cancer drugs, increasing the solubility 
and hence the availability of the drug.
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